Evidence before promotion
Research Reference Library
A compliance-reviewed index derived from the September 15, 2026 master reference. The source remains a work in progress. Numerical protocols, routes, timing, cycles, stacks, treatment claims, patient-management statements, and anecdotal applications are intentionally excluded.
Somatropin
Recombinant human growth hormone reference material for analytical and endocrine-pathway research.
Approved-drug contextPrescription somatropin products have product-specific approvals. That evidence does not confer approval on an RUO reference material.
Regulatory boundary: Not an FDA-approved somatropin drug product and not offered here for clinical use.
SS-31
Mitochondria-targeted tetrapeptide reference material investigated for cardiolipin binding and inner-membrane biology.
Approved-drug contextHuman research exists across mitochondrial-disease programs. FDA accelerated approval applies only to the branded product Forzinity for a specific Barth syndrome indication.
Regulatory boundary: An RUO SS-31 material is not Forzinity and has no implied FDA approval.
CJC-1295 without DAC + Ipamorelin
Dual reference material for laboratory study of GHRH-receptor and growth-hormone-secretagogue receptor pathways.
Limited human evidenceHuman studies exist for long-acting CJC-1295 and for ipamorelin separately; evidence for the exact no-DAC combination is limited.
Regulatory boundary: No clinical-use or combination-efficacy claim is made.
KPV
Alpha-MSH-derived tripeptide reference material investigated in cellular inflammatory-signaling models.
Preclinical / mechanisticThe published evidence base is predominantly preclinical; no established human therapeutic regimen is represented.
Regulatory boundary: Research reference only.
Bacteriostatic Water
Diluent reference included in the supplied source list; it is not an active peptide.
Laboratory supplyNo therapeutic peptide evidence applies. Public reconstitution and injection instructions are intentionally excluded.
Regulatory boundary: Not listed for sale pending independent regulatory and product review.
Tesamorelin
GHRH-analogue reference material for receptor-binding and analytical research.
Approved-drug contextAn FDA-approved prescription product exists for a specific indication. That status does not apply to an RUO reference material.
Regulatory boundary: Not an FDA-approved tesamorelin drug product and not offered here for clinical use.
Epitalon / Epithalon
Pineal tetrapeptide reference material used in circadian, retinal, and cellular-aging research models.
Limited human evidenceHuman therapeutic evidence is limited; much of the longevity discussion remains preclinical.
Regulatory boundary: No anti-aging, sleep, retinal, or other clinical benefit is claimed.
MOTS-c
Mitochondrial-derived peptide reference material investigated in energy-sensing and metabolic-signaling models.
Preclinical / mechanisticMechanistic and preclinical research is substantial, but no completed human program establishing a therapeutic dose is represented.
Regulatory boundary: Research reference only.
Semax
ACTH-fragment-derived neuropeptide reference material for analytical and neurobiology research.
Limited human evidenceHuman clinical literature exists but is relatively small and regionally concentrated.
Regulatory boundary: No cognitive, neurologic, or other clinical benefit is claimed.
ARA-290
Erythropoietin-derived peptide reference material investigated in tissue-protective receptor signaling.
Early human researchEarly Phase 2 human evidence exists in specific research contexts.
Regulatory boundary: No pain, neuropathy, or other clinical benefit is claimed.
DSIP
Neuropeptide reference material for analytical and neuroendocrine research.
Limited human evidenceSmall historical human studies produced mixed findings; no modern therapeutic regimen is established.
Regulatory boundary: No sleep, recovery, stress, or other clinical benefit is claimed.
Selank
Tuftsin-derived reference material for analytical and neuropeptide research.
Limited human evidenceThe human evidence base is limited and concentrated in regional studies.
Regulatory boundary: No anxiety, cognitive, or other clinical benefit is claimed.
Thymosin Alpha-1
Thymic peptide reference material for immune-signaling and analytical research.
Human clinical researchRandomized human studies exist in specific contexts; this library does not translate those protocols into consumer directions.
Regulatory boundary: No immune-treatment or disease claim is made.
Glutathione
Endogenous antioxidant reference material used in redox-homeostasis and analytical research.
Human clinical researchHuman evidence exists, but findings are route- and indication-specific and do not establish a general wellness use.
Regulatory boundary: No detoxification, wellness, or treatment claim is made.
hCG
Glycoprotein-hormone reference material for receptor-binding and endocrine-pathway research.
Approved-drug contextPrescription hCG products have product-specific approvals. That evidence does not confer approval on an RUO material.
Regulatory boundary: Not an FDA-approved hCG drug product and not offered here for clinical use.
Pinealon
Short-peptide reference material investigated in experimental neurobiology and oxidative-stress models.
Preclinical / mechanisticThe evidence base is predominantly preclinical, with no robust human dose-ranging program identified in the supplied reference.
Regulatory boundary: Research reference only.
Retatrutide
Investigational triple-receptor agonist reference material for analytical and receptor-binding research.
Human clinical researchRandomized human trial evidence exists, but retatrutide remains investigational and this library provides no use or dosing guidance.
Regulatory boundary: Not an FDA-approved drug product and not listed for purchase on this site.
TB-500
Reference material associated with thymosin-beta-4 biology and laboratory study of actin and cell-migration pathways.
Preclinical / mechanisticHuman thymosin-beta-4 studies are not automatically equivalent to a commercial TB-500 preparation.
Regulatory boundary: No tissue-repair, injury, or other clinical benefit is claimed.
BPC-157
Synthetic pentadecapeptide reference material used in analytical and cellular-signaling research.
Preclinical / mechanisticThe evidence base is predominantly preclinical. Very limited human safety data do not establish therapeutic efficacy.
Regulatory boundary: No repair, injury, gastrointestinal, or other clinical benefit is claimed.
NAD+
Redox-coenzyme reference material for mitochondrial-energy, enzyme, and analytical research.
Early human researchEmerging human evidence is route- and indication-specific; repeated wellness protocols have a thinner evidence base.
Regulatory boundary: No energy, longevity, or wellness benefit is claimed.
PT-141
Melanocortin-receptor agonist reference material for receptor-binding and analytical research.
Approved-drug contextAn FDA-approved prescription bremelanotide product exists for a specific population and indication; that status does not apply to RUO material.
Regulatory boundary: Not an FDA-approved bremelanotide drug product and not offered here for clinical use.
GHK-Cu
Copper-binding tripeptide reference material for analytical and extracellular-matrix research.
Limited human evidenceHuman topical research exists, but an established systemic injectable clinical regimen was not identified.
Regulatory boundary: No systemic, injectable, anti-aging, or tissue-repair benefit is claimed.
Research Use Only. The reference materials described on this site are intended solely for qualified laboratory research. They are not medicines, supplements, foods, cosmetics, or medical devices; they are not for human or veterinary use, ingestion, injection, diagnosis, treatment, cure, mitigation, prevention, or alteration of the structure or function of the body. A compound name may also identify an ingredient used in an approved or investigational drug, but no statement on this site implies that an RUO material is an FDA-approved product or is safe or effective for clinical use.